Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6190)
  2. Meeting Abstract (6164)
  3. Review (400)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (159)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11087)
  2. Hematologic Malignancies, Division of (10638)
  3. GSK Faculty (5447)
  4. Adult Leukemia (3721)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (944)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (308)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (267)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1668)
  3. Nature Publishing Group (1117)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13544)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma
    Journal Article

    Horwitz, S. M.; Feldman, T. A.; Ye, J. C.; Khodadoust, M. S.; Munoz, J.; Hamlin, P. A.; Kim, Y. H.; Wilcox, R. A.; Patel, M. R.; Coffey, G.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: A plain language summary
    Review

    Marks, D. I.; Cassaday, R. D.; Ribera, J. M.; Schuh, A. C.; Park, J. H.; Chiaretti, S.; Stelljes, M.
    Expert Review of Hematology (2025)

    Fulltext@MSK | Save
  • RAG suppresses group 2 innate lymphoid cells
    Journal Article

    Ver Heul, A. M.; Mack, M.; Zamidar, L.; Tamari, M.; Yang, T. L.; Trier, A. M.; Kim, D.; Janzen-Meza, H.; Van Dyken, S. J.; Hsieh, C. S.; more...
    eLife (2025)

    Fulltext@MSK | Save
  • Epichaperomes: Redefining chaperone biology and therapeutic strategies in complex diseases
    Review

    Pasala, C.; Digwal, C. S.; Sharma, S.; Wang, S.; Bubula, A.; Chiosis, G.
    RSC Chemical Biology (2025)

    Fulltext@MSK | Save
  • US geriatric assessment practices for older adults undergoing hematopoietic cell transplantation or chimeric antigen receptor T cell therapy: An American Society for Transplantation and Cellular Therapy Physician survey from the Aging Special Interest Group and Committee on Practice Guidelines
    Guidelines

    Munshi, P. N.; Olin, R. L.; Wall, S.; McCurdy, S. R.; Al-Juhaishi, T.; Baker, J.; Bhatt, V. R.; Chokr, N.; Dahi, P.; DeFilipp, Z.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: A randomized phase 3 trial
    Journal Article

    Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: Phase 1 study final results
    Journal Article

    Cortes, J. E.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
    Journal Article

    Shah, B. D.; Cassaday, R. D.; Park, J. H.; Houot, R.; Logan, A. C.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; O’Dwyer, K. M.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results: CHRONIC MYELOID LEUKEMIA
    Journal Article

    Hochhaus, A.; Kim, D. W.; Cortes, J. E.; Sasaki, K.; Mauro, M. J.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel/ALLO-501 in relapsed/refractory large B-cell lymphoma: Phase I experience from the ALPHA2/ALPHA clinical studies
    Journal Article

    Locke, F. L.; Munoz, J. L.; Tees, M. T.; Lekakis, L. J.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S. A.; Shouse, G. P.; Hamadani, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save